Table 1.
Patient characteristics according to age group (n = 529)
| Characteristic | Age <65 (n = 277), n (%) | Age ≥65 (n = 252), n (%) | p value |
|---|---|---|---|
| Age, median (range) | 56 (31–64) | 71 (65–86) | <.0001 |
| <45 yr | 18 (6.5) | ||
| 45–54 yr | 99 (35.7) | ||
| 55–64 yr | 160 (57.8) | ||
| 65–74 yr | 203 (80.6) | ||
| ≥75 yr | 49 (19.4) | ||
| ECOG performance status | .28 | ||
| 0 | 75 (27.1) | 83 (32.9) | |
| 1 | 156 (56.3) | 126 (50.0) | |
| 2 | 46 (16.6) | 43 (17.1) | |
| Sex | .71 | ||
| Male | 190 (68.6) | 169 (67.1) | |
| Female | 87 (31.4) | 83 (32.9) | |
| Race a | .16 | ||
| White | 205 (79.8) | 203 (84.6) | |
| Other | 52 (20.2) | 37 (15.7) | |
| Stage IV NSCLC | 192 (69.8) | 378 (72.3) | .19 |
| Histology | .26 | ||
| Adenocarcinoma | 156 (56.3) | 125 (49.6) | |
| Squamous | 51 (18.4) | 58 (23.0) | |
| Other histology | 70 (25.3) | 69 (27.4) | |
| Treatment arm | .30 | ||
| Carboplatin, paclitaxel | 138 (49.8) | 137 (54.4) | |
| Paclitaxel | 139 (50.2) | 115 (45.6) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NSCLC, non‐small cell lung cancer.
a
Race information was missing for 20 younger adults and 12 older adults.